Magenta therapeutics, inc. (MGTA)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Revenue

0

0

0

0

0

0

0

0

0

0

0

Operating expenses:
Research and development

62,634

59,208

52,884

47,778

44,028

41,340

34,160

36,558

0

0

0

General and administrative

25,229

23,761

23,378

22,542

20,979

18,623

14,888

11,519

0

0

0

Total operating expenses

87,863

82,969

76,262

70,320

65,007

59,963

49,048

48,077

0

0

0

Loss from operations

-87,863

-82,969

-76,262

-70,320

-65,007

-59,963

-49,048

-48,077

0

0

0

Interest and other income, net

5,917

6,200

6,051

5,084

3,819

2,448

1,299

0

0

0

-

Net loss

-81,946

-76,769

-70,211

-65,236

-61,188

-57,515

0

0

0

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

0

-

0

0

Cumulative dividends on redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

0

Reversal of cumulative dividends on redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

0

Net loss attributable to common stockholders

-

-

-70,211

-65,236

-

-57,603

-47,843

-47,215

0

0

0

Net loss per share, basic and diluted

-0.51

-0.61

-0.54

-0.48

-0.44

5.02

-0.49

-3.13

-4.53

-3.44

-8.90

Weighted average common shares outstanding, basic and diluted

39,364

39,150

38,824

36,662

33,422

33,703

32,997

4,391

2,466

2,009

1,728

Comprehensive loss:
Net loss

-81,946

-76,769

-70,211

-65,236

-61,188

-57,515

0

0

0

-

-

Other comprehensive income:
Unrealized gains on marketable securities

322

16

0

0

0

-

-

-

-

-

-

Total other comprehensive income

322

16

0

0

0

-

-

-

-

-

-

Total comprehensive loss

-81,624

-76,753

-70,128

-65,097

-61,147

-57,523

-47,749

-47,465

0

0

0